yct-529
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2023 (NCT06094283)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Retinol-binding protein 1AGONIST
RBP1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C2=CC(C)(C)Oc3ccc(-c4ccc(-c5ccc(C(=O)O)cc5)[nH]4)cc32)cc1- Mol. weight
- 435.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5499704 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06542237 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2024 | New Zealand Clinical Research, YourChoice Therapeutics, Inc. |
| NCT06094283 | Phase 1 | Nov 30, 2023 | Quotient, YourChoice Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| YourChoice Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2023 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2024 |
| Quotient | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1